Ingenol mebutate (IM) is a topical pharmacotherapy approved in Switzerland since 2012 for treating non-hypertrophic, non-hyperkeratotic actinic keratosis (AK). We report 2 cases with off-label use of IM. The first case of bowenoid AK was treated with 150 μg IM for 3 consecutive days with an almost complete clinical remission of the lesion. The second case of Bowen's disease was treated with 500 μg IM for 2 consecutive days leading to complete clinical remission.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1159/000447390 | DOI Listing |
Publication Analysis
Top Keywords
actinic keratosis
8
bowen's disease
8
disease treated
8
ingenol mebutate
8
μg consecutive
8
consecutive days
8
complete clinical
8
clinical remission
8
bowenoid actinic
4
keratosis bowen's
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!